Kazia Therapeutics (KZIA) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kazia Therapeutics has announced promising results from the GBM AGILE phase II/III trial for their drug paxalisib, showing a significant improvement in overall survival for newly diagnosed unmethylated glioblastoma patients. The company plans to discuss accelerated approval pathways with the FDA, following favorable outcomes which include an approximate 33% increase in survival compared to current standard treatments. Paxalisib has been well-tolerated with consistent secondary analysis results, and full data is expected to be presented later in the year.
For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.